Answers are grounded in this paper and cite their sources.
Review demonstrates targeting inflammation to prevent recurrent stroke across diverse etiologies, indicating serum biomarkers can guide patient selection.
Evidence points toward the importance of inflammation across multiple stroke etiologies and potential benefit of anti-inflammatory targets in secondary stroke prevention. Taking the heterogeneous stroke etiologies into account, the use of serum biomarkers could be useful to identify patients with residual inflammatory risk and perform biomarker-led patient selection for future RCTs.
No takes yet. Share an insight, caveat, or question.
Zietz et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: